Literature DB >> 1057444

Adenosine deaminase activity in leukaemia.

J F Smyth, K R Harrap.   

Abstract

Adenosine deaminase (EC 3.5.4.4., ADA) has been measured in the blast cells of 36 patients with acute lymphoblastic, acute myeloid, chronic myeloid and chronic myeloid blast crisis leukaemia. Particularly high levels were found in acute lymphoblastic and chronic myeloid blast crisis patients. The measurement of ADA may be useful diagnostically in the undifferentiated acute leukaemias and in detecting the early onset of blast crisis in chronic myeloid leukaemia. Possible reasons for the elevation of ADA in malignant cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1057444      PMCID: PMC2009433          DOI: 10.1038/bjc.1975.95

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  SERUM ADENOSINE DEAMINASE IN THE DIFFERENTIAL DIAGNOSIS OF JAUNDICE.

Authors:  D M GOLDBERG
Journal:  Br Med J       Date:  1965-02-06

2.  A STUDY OF THE TISSUE DISTRIBUTION OF ADENOSINE DEAMINASE IN SIX MAMMAL SPECIES.

Authors:  T G BRADY; C I O'DONOVAN
Journal:  Comp Biochem Physiol       Date:  1965-01

3.  Adenosine deaminase activity in lymphoid cells during antibody production.

Authors:  J G HALL
Journal:  Aust J Exp Biol Med Sci       Date:  1963-02

4.  Serum adenosine deaminase: methodology and clinical applications.

Authors:  L H KOEHLER; E J BENZ
Journal:  Clin Chem       Date:  1962-04       Impact factor: 8.327

5.  The deaminases of adenosine and adenylic acid in blood and tissues.

Authors:  E J Conway; R Cooke
Journal:  Biochem J       Date:  1939-04       Impact factor: 3.857

6.  Adenosine deaminase.

Authors:  T Brady
Journal:  Biochem J       Date:  1942-06       Impact factor: 3.857

7.  Multiple forms of human adenosine deaminase. II. Isolation and properties of a conversion factor from human lung.

Authors:  H Nishihara; S Ishikawa; K Shinkai; H Akedo
Journal:  Biochim Biophys Acta       Date:  1973-04-12

8.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

9.  Evidence for control of several different tissue-specific isozymes of adenosine deaminase by a single genetic locus.

Authors:  R Hirschhorn; V Levytaka; B Pollara; H J Meuwissen
Journal:  Nat New Biol       Date:  1973-12-19

10.  Adult acute leukaemia.

Authors:  K Atkinson; D G Wells; H M Clink; H E Kay; R Powles; T J McElwain
Journal:  Br J Cancer       Date:  1974-09       Impact factor: 7.640

View more
  21 in total

1.  PORPHOBILINOGEN DEAMINASE AND ADENOSINE DEAMINASE ACTIVITY AS A POSSIBLE DIAGNOSTIC AID IN LYMPHATIC LEUKEMIAS.

Authors:  Alka N Sontakke; Y V Sharma
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia.

Authors:  J F Smyth; D G Poplack; B J Holiman; B G Leventhal; G Yarbro
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

3.  In vivo toxicity to lymphoid tissue by 2'-deoxycoformycin.

Authors:  J F Smyth; R C Young; D M Young
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

4.  Acute lymphoblastic leukemia hand-mirror cells. Study of nine cases.

Authors:  V Liso; G Specchia; V Pavone; F Colotta; A Riezzo; A Ferrannini; A Tursi
Journal:  Blut       Date:  1983-11

5.  Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations.

Authors:  R Tung; R Silber; F Quagliata; M Conklyn; J Gottesman; R Hirschhorn
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

Review 6.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

Review 7.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.

Authors:  J F Smyth; R M Paine; A L Jackman; K R Harrap; M M Chassin; R H Adamson; D G Johns
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

9.  Blood lymphocytes in chronic lymphocytic leukaemia and Hodgkin's disease: Immunological features and enzymes of nucleoside metabolism.

Authors:  F Ambrogi; B Grassi; S Ronca-Testoni; G Ronca
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

10.  Identification of actinomycins by high performance liquid chromatography and fast atom bombardment mass spectrometry.

Authors:  S Cho; Y M Goo; K J Kim
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.